Covidien Ltd. (NYSE: COV, BSX: COV) today announced that one of its
subsidiaries has acquired 100% ownership of Tissue Science Laboratories
a medical device company dedicated to the research, development and
commercialization of tissue implant products for surgical and wound care
therapies. Covidien launched a public tender offer in the United Kingdom
for all of Tissue Science Laboratories outstanding shares held by UK
residents on March 12, 2008. Covidien has also completed the sale of its European Incontinence
business to a private French company who will rename the business Lille
Healthcare. Terms of the agreement were not disclosed. The business
which is headquartered in Lille, France, was formerly part of Covidien´s
Medical Supplies segment and had sales of $109 million in fiscal 2007. ABOUT COVIDIEN LTD. Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien manufactures
distributes and services a diverse range of industry–leading product
lines in four segments: Medical Devices, Imaging Solutions
Pharmaceutical Products and Medical Supplies. With 2007 revenue of
nearly $9 billion, Covidien has more than 42,000 employees worldwide in
57 countries, and its products are sold in over 130 countries. Please
visit www.covidien.com to learn
more about our business.
